A Cross-Sectional Retrospective Study of Non-Splenectomized and Never-Treated Patients with Type 1 Gaucher Disease
Authors:
- Christine SerratriceCSChristine Serratrice
- Jérôme StirnemannJSJérôme Stirnemann
- Amina BerrahalABAmina Berrahal
- Nadia BelmatougNBNadia Belmatoug
- Fabrice CamouFCFabrice Camou
- Catherine CaillaudCCCatherine Caillaud
- Thierry Billette de VillemeurTVThierry Billette de Villemeur
- Florence DalbiesFDFlorence Dalbies
- Bérengère CadorBCBérengère Cador
- Roseline FroissartRFRoseline Froissart
- Agathe MasseauAMAgathe Masseau
- Anaïs BrassierABAnaïs Brassier
Open Access
- 22 July 2020
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (8) , 2343
Abstract
Patients with type 1 Gaucher disease (GD1) present thrombocytopenia, anemia, organomegaly, and bone complications. Most experts consider that the less aggressive forms do not require specific treatment. However, little is known about the disease course of these forms. The objective of this cross-sectional retrospective study was to compare the clinical, radiological, and laboratory characteristics of patients with less severe GD1 at diagnosis and at the last evaluation to identify features that might lead to potential complications. Non-splenectomized and never-treated patients (19 women and 17 men) were identified in the French Gaucher Disease Registry (FGDR). Their median age was 36.6 years (2.4–75.1), and their median follow-up was 7.8 years (0.4–32.4). Moreover, 38.7% were heterozygous for the GBA1 N370S variant, and 22.6% for the GBA1 L444P variant. From diagnosis to the last evaluation, GD1 did not worsen in 75% of these patients. Some parameters improved (fatigue and hemoglobin concentration), whereas platelet count and chitotriosidase level remained stable. In one patient (2.7%), Lewy body dementia was diagnosed at 46 years of age. Bone lesion onset was late and usually a single event in most patients. This analysis highlights the genotypic heterogeneity of this subgroup, in which disease could remain stable and even improve spontaneously. It also draws attention to the possible risk of Lewy body disease and late onset of bone complications, even if isolated, to be confirmed in larger series and with longer follow-up.Keywords
Funding Information
- Shire International GmbH, now part of Takeda (IIR-FRA-001381)
This publication has 29 references indexed in Scilit:
- Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literatureBritish Journal of Haematology, 2013
- Revised recommendations for the management of Gaucher disease in childrenEuropean Journal of Pediatrics, 2012
- The role of saposin C in Gaucher diseaseMolecular Genetics and Metabolism, 2012
- The French Gaucher’s disease registry: clinical characteristics, complications and treatment of 562 patientsOrphanet Journal of Rare Diseases, 2012
- Type 1 Gaucher DiseaseArchives of internal medicine (1960), 2010
- Spontaneous regression of disease manifestations can occur in type 1 Gaucher disease; results of a retrospective cohort studyBlood Cells, Molecules, and Diseases, 2010
- The clinical course of untreated Gaucher disease in 22 patients over 10 years: Hematological and skeletal manifestationsBlood Cells, Molecules, and Diseases, 2009
- Type 1 Gaucher Disease: Phenotypic Expression and Natural History in Japanese PatientsBlood Cells, Molecules, and Diseases, 1998
- The Clinical Course of Treated and Untreated Gaucher Disease. A Study of 45 PatientsBlood Cells, Molecules, and Diseases, 1995
- Gaucher DiseaseMedicine, 1992